Literature DB >> 18795258

Opioid and benzodiazepine contributions to etomidate-associated adrenal insufficiency.

Harry Daniell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18795258     DOI： 10.1007/s00134-008-1264-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  6 in total

1.  Chronic fentanyl application induces adrenocortical insufficiency.

Authors:  K M Oltmanns; H L Fehm; A Peters
Journal:  J Intern Med       Date:  2005-05       Impact factor: 8.989

2.  Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects.

Authors:  R S Rittmaster; G B Cutler; D O Sobel; D S Goldstein; M C Koppelman; D L Loriaux; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1985-05       Impact factor: 5.958

Review 3.  Acute adrenal insufficiency after a single dose of etomidate.

Authors:  Jonathan B Lundy; Matthew L Slane; James D Frizzi
Journal:  J Intensive Care Med       Date:  2007 Mar-Apr       Impact factor: 3.510

4.  Duration of adrenal inhibition following a single dose of etomidate in critically ill patients.

Authors:  Marc Vinclair; Christophe Broux; Patrice Faure; Julien Brun; Céline Genty; Claude Jacquot; Olivier Chabre; Jean-François Payen
Journal:  Intensive Care Med       Date:  2007-12-18       Impact factor: 17.440

5.  Regulation of adrenocortical steroidogenesis by benzodiazepines.

Authors:  I Thomson; R Fraser; C J Kenyon
Journal:  J Steroid Biochem Mol Biol       Date:  1995-06       Impact factor: 4.292

6.  One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis.

Authors:  Marieke den Brinker; Anita C S Hokken-Koelega; Jan A Hazelzet; Frank H de Jong; Wim C J Hop; Koen F M Joosten
Journal:  Intensive Care Med       Date:  2007-08-21       Impact factor: 17.440
  6 in total
  1 in total

Review 1.  Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.

Authors:  Maria Fleseriu; Frederic Castinetti
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.